AstraZeneca
-
Potential losses exceed $300 billion! Nearly 200 drugs are facing a patent cliff
For more reports, please follow DrugTimes
-
AstraZeneca strengthens its cardiovascular pipeline with agreement for a pre-clinical novel lipid-lowering therapy
Congratulations to CSPC and AstraZeneca!
-
The Past and Present of ‘Miraculous Medicine’ Roxadustat
Roxadustat is a domestically produced Class 1 innovative drug originating from the United …
-
TOP PHARMAS BY 2024 PIPELINE SIZE
For more info, please visit https://www.drugtimes.cn/english-content
